https://www.thebodypro.com/category/hiv-treatments-in-development/tag/news

The Latest

injectable

Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable

Questions still remain as to when FDA will approve, and how it will be implemented.

Marrazzo at CROI

CROI 2020: What to Expect in HIV Science From This Year’s Conference

COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.

pregnant woman and partner cuddling on couch

New Study Will Test Safety of PrEP and Dapivirine Ring in Pregnancy

While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.

doctor drawing blood from patient

NIH, Gates Foundation Hatch Plan to Develop Affordable Gene Therapy for HIV, Sickle Cell Disease

The new public-private partnership will put $200 million toward finding eventual cures for two of the world's most pervasive diseases.

Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

Physician or nurse giving injection in patient's arm

Study Finds Long-Acting HIV Meds Are Acceptable to Many People, but Differences Exist Among Groups

People with college education, gay and bisexual men, and people who struggle to make clinic visits were more likely to prefer the long-acting option.

Close up of sneakers walking up stairs

This Week in HIV Research: One Step at a Time

June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.

Magnifying glass on antique anatomy book: Heart image

This Week in HIV Research: Matters of the Heart

May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.

The Genetic Mutation Behind the Only Apparent Cure for HIV Img

The Genetic Mutation Behind the Only Apparent Cure for HIV

The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?